U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07242014) titled '68Ga-XACP3 PET/CT in Prostate Cancer' on Nov. 17.
Brief Summary: The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET/CT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET/CT.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
PET/CT
ACP3
Intervention:
DIAGNOSTIC_TEST: Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET/CT), 68Ga-XACP3 PET/CT
Each subject receives a single intravenous injection of standard-of-care imaging radiopharmaceutical (68Ga-PSMA) and 68Ga-XACP3, and undergoes PET/CT imaging within the specified time....